HIV and Cardiovascular Health: Understanding the Increased Risk

For individuals living with HIV (PLWH), advancements in antiretroviral therapy (ART) have dramatically extended life expectancy. However, this increased longevity has brought a new set of health challenges to the forefront, most notably a significantly elevated risk of cardiovascular disease (CVD). While ART effectively manages the viral load, it doesn’t eliminate the increased susceptibility to heart problems. This article explores the complex relationship between HIV and CVD, current research, and strategies for mitigating risk.

The Link Between HIV and Cardiovascular Disease

Historically, CVD was less prevalent in PLWH due to shorter life expectancies. However, as ART has enabled people with HIV to live longer, the incidence of CVD has risen sharply. Studies now demonstrate that PLWH have up to twice the risk of developing cardiovascular disease compared to HIV-negative individuals [1]. This increased risk isn’t solely linked to traditional risk factors like high blood pressure or cholesterol, nor is it fully explained by ART itself [1].

Inflammation and Immune Dysfunction

A key factor contributing to the higher CVD risk in PLWH is chronic inflammation. HIV attacks the central control mechanisms of the immune response, leading to systemic and vascular inflammation [3]. Even with effective viral suppression, immune activation persists, contributing to atherosclerosis – the buildup of plaque in the arteries. Both innate and adaptive immune systems play a role in this inflammatory process [3].

Specific Cardiovascular Manifestations

PLWH are at increased risk for a range of cardiovascular complications, including:

• Myocardial Infarction (Heart Attack): The risk of heart attack is significantly higher in PLWH.
• Heart Failure: The heart’s ability to pump blood effectively can be compromised.
• Sudden Cardiac Death: An unexpected cessation of heart function.
• Coronary Artery Disease: Moderate to severe coronary disease prevalence ranges from 0% to 52% in PLWH [2].
• Myocardial Fibrosis: Fibrosis, or scarring, of the heart muscle is observed in 5% to 84% of PLWH [2].

Managing Cardiovascular Risk in PLWH

Recent research offers promising strategies for reducing CVD risk in PLWH. The REPRIEVE trial, a large-scale study, demonstrated that pitavastatin calcium significantly lowered the risk of major adverse cardiovascular events (MACE) in PLWH [1]. Specifically, the hazard ratio was 0.65 (95% CI, 0.48-0.90; P =.002) compared to placebo [1].

Beyond statins, comprehensive risk management includes:

• Lifestyle Modifications: Quitting smoking, maintaining a healthy weight, and adopting a heart-healthy diet are crucial.
• Blood Pressure Control: Aggressive management of hypertension is essential.
• Cholesterol Management: Regular monitoring and treatment of high cholesterol levels.
• Regular Monitoring: Routine cardiovascular screenings are vital for early detection and intervention.

Allergies and Immune Response in PLWH

Interestingly, HIV can also impact the immune system in ways that affect allergic responses. While the incidence of atopy (a predisposition to allergies) is similar between PLWH and HIV-negative individuals, drug sensitivities are significantly higher in PLWH [1]. Allergen immunotherapy (AIT) is being investigated as a potential treatment option for allergic respiratory diseases in PLWH, with early studies suggesting it may be safe and effective, particularly in those with early or middle-stage disease [1].

Looking Ahead

The intersection of HIV and cardiovascular health is a growing area of research. Continued investigation into the mechanisms driving increased CVD risk in PLWH, coupled with the implementation of effective prevention and treatment strategies, is essential to improve the long-term health and quality of life for this population. As ART continues to advance and life expectancies increase, proactive cardiovascular care will develop into even more critical.